Abstract
‘Exhaustion’ is a term used to describe a state of native and redirected T-cell hypo-responsiveness resulting from persistent antigen exposure during chronic viral infections or cancer. Although a well-established phenotype across mice and humans, exhaustion at the molecular level remains poorly defined and inconsistent across the literature. This is, in part, due to an overreliance on surface receptors to define these cells and explain exhaustive behaviours, an incomplete understanding of how exhaustion arises, and a lack of clarity over whether exhaustion is the same across contexts, e.g. chronic viral infections versus cancer. With the development of systems-based genetic approaches such as single-cell RNA-seq and CRISPR screens applied to in vivo data, we are moving closer to a consensus view of exhaustion, although understanding how it arises remains challenging given the difficulty in manipulating the in vivo setting. Accordingly, producing and studying exhausted T-cells ex vivo are burgeoning, allowing experiments to be conducted at scale up and with high throughput. Here, we first review what is currently known about T-cell exhaustion and how it’s being studied. We then discuss how improvements in their method of isolation/production and examining the impact of different microenvironmental signals and cell interactions have now become an active area of research. Finally, we discuss what the future holds for the analysis of this physiological condition and, given the diversity of ways in which exhausted cells are now being generated, propose the adoption of a unified approach to clearly defining exhaustion using a set of metabolic-, epigenetic-, transcriptional-, and activation-based phenotypic markers, that we call ‘M.E.T.A’.
Keywords: T-cell activation, T-cell exhaustion, immunotherapy, inhibitory receptors, in vitro exhaustion
Introduction
The exhaustion of cytotoxic T-cells was originally described in the context of chronic lymphocytic choriomeningitis virus (LCMV) infections of mice in which the depletion of functional effector cells was noted [1]. Several years later it was shown that these cells were not depleted but were instead present but dysfunctional [2]. The process of how effector T-cells become dysfunctional has been a topic of interest for many years, whose study has especially benefited from advancements in the fields of single-cell transcriptomics and T-cell receptor (TCR) sequencing. These methods allow mapping of the transcriptomic profile of a heterogeneous cell population in combination with the identification of antigen-specific T cells, without relying on functional readouts. With the help of these new approaches, it is now known that exhausted T cells comprise distinct immune cell types of a specific lineage that differ from effector or memory T cells and play a central role in cancer, autoimmunity and chronic infections.
In its simplest sense, T-cell exhaustion refers to a dysfunctional state of the T cell that is characterized by an impaired ability to respond to infected cells or tumours. In a chronic infection state, the lingering presence of an invading pathogen leads to prolonged antigen stimulation resulting in T-cell dysfunction. In a tumour setting, T cells become exhausted due to chronic antigen exposure leading to reduced effector function [loss of interleukin-2 (IL-2), tumour necrosis factor alpha (TNF-α) and Interferon-gamma (IFN-γ) production]. Accordingly, CD8+ cells can infiltrate the tumour microenvironment (TME) but are then unable to mount an effective anti-tumour response, allowing continued growth of the tumour. The exhausted state of a T cell is driven by a unique transcriptional programme that generates a specific phenotypic state.
Much of the current interest in T-cell exhaustion resulted from the discovery that it imposes major constraints on the therapeutic efficacy of chimeric antigen receptor (CAR) T cells, prompting attempts to create exhaustion-resistant or -reversible CAR T-cell platforms (see, e.g. Refs [3–5] as an example of the work of just one laboratory). However, how exhausted T cells emerge has been a field of active study for many years. Early studies on T-cell exhaustion suggested that previously functional T cells terminally differentiate to become exhausted T cells. But with the emergence of single-cell techniques and the ability to characterize the cell populations based on transcriptomic profiles, this model is having to be revised. A T-cell exhaustion programme is now thought to occur alongside the normal differentiation of T cells [6]. The notion is also that cells at any stage of differentiation can initiate the exhaustion programme. The way exhausted cells are defined is also changing and it is thought that among ‘exhausted’ T cells, there exists a subset of precursors that proliferate and constantly replenish a pool of terminally differentiated cells that are proliferation-incompetent and are sometimes referred to as ‘truly’ exhausted T cells [7, 8].
The different types of exhausted T cells, their biology, developmental paths and their transcriptional and epigenetic features have been comprehensively reviewed previously [9, 10]. Here, we consider how exhausted T cells can be defined based on transcription factor activity, expression of inhibitory receptors, effector functions, metabolic status and epigenetic status. We also discuss the new ex vivo and in vitro approaches for generating exhausted T cells and how these definitions are being used to identify these cells. For the purposes of this review, we will focus mainly on the biology of CD8+ T cells.
The different definitions of exhausted T cells
Transcriptomic properties/states of exhausted T cells
Understanding their transcriptional programmes is key to the identification of the cellular processes leading to the differentiation of any cell type. Studies that characterize cell-type-specific gene-regulatory networks in exhausted T cells have been crucial in this regard and a clear conclusion from these studies is that these cells have a transcriptional profile which is different from that of memory or effector CD8+ T cells, not only in terms of the differential expression of transcription factors (TFs), but also in the way the expressed transcription factors in turn regulate the underlying gene-regulatory networks. Using transcription factor expression profiles is a commonly deployed approach to define the exhaustion state. More comprehensive studies combine the expression profiles and gene-regulatory networks driven by the transcription factors, including TOX, nuclear receptor subfamily 4 group A (NR4A), T-bet, EOMES, nuclear factor of activated T-cells (NFAT) and other NFAT-driven and TCR-responsive transcription factors (such as IRF4 and BATF) to characterize exhaustion states [11].
The NFAT family of transcription factors comprises a class of very well-studied proteins in relation to T-cell activation, T-cell anergy and T-cell exhaustion. T cells express three of the four calcium-regulated NFAT proteins: NFAT1, NFAT2 and NFAT4. The functions of NFAT transcription factors depend on the T-cell differentiation state. In the setting of activation, NFAT proteins work coordinately with activator protein 1 (AP1) transcription factors, forming heterodimers that promote the transactivation of many cytokine genes [12]. In the context of chronic LCMV infection, the expression balance of NFAT and AP-1 shifts towards high NFAT expression, leading to the formation of NFAT homodimers. NFAT homodimers, on the other hand, bind to the promoter regions of a number of genes encoding inhibitory receptors, such as PDCD1, LAG-3 and HAVCR2 (the gene encoding TIM-3) [13, 14]. In addition to NFAT, other transcription factors, such as IRF4 [15], BATF [16] and NR4A1 [17], which function downstream of TCR signalling, also contribute to the formation of the exhausted state. These transcription factors are mostly known to be involved in the expression of multiple inhibitory receptors including PD-1, in this way constraining effector function.
Transcription factors such as T-bet and EOMES have very distinct roles in effector and memory cells compared with exhausted cells. T-bet drives the expression of effector molecules such as IFN-γ in effector cells whereas EOMES is important for memory formation. In effector cells, T-bet also represses the expression of PD-1 [18]. In chronic viral infections, the expression of T-bet is reduced in virus-specific CD8+ T cells, with the level of reduction correlating with the degree of T-cell effector dysfunction. EOMES expression, on the other hand, is upregulated in exhausted CD8+ T cells during chronic infection [19]. In addition to expression differences, the gene-regulatory networks controlled by EOMES are highly context-specific and the exhausted-cell network overlaps very little with that of effector or memory cells [20]. Recent work suggests that the relative level of T-bet and EOMES in T-cells could define exhaustion since, in LCMV infections, exhausted cells had a higher ratio of nuclear EOMES: T-bet than memory T cells [21].
Another transcription factor with a key role in T-cell exhaustion is TCF-1, which is encoded by TCF7. TCF-1 has been previously implicated in the production and maintenance of memory CD8+ cells and has been suggested to have a similar role in the maintenance of stem-like pre-exhausted cells [8]. Chen et al. [22] used single-cell RNA-seq and lineage tracking in the LCMV-infection mouse model of exhaustion and found that the separation of effector from exhausted CD8+ T-cell lineages is mediated by TCF-1 early during chronic infection. The exhaustion lineage in this model was marked by expression of PD-1 and TCF-1 and characterized by low expression of Gzmb and Klrg1, whereas the effectors included cells expressing terminal differentiation markers such as TIM-3 and CD39. In the exhaustion cells, TCF7 might also coordinate transcriptional networks involving EOMES, c-Myb, and Bcl-2, which are known to reinforce exhaustion and persistence.
One of the newest transcription factors implicated in exhaustion is the Thymocyte selection-associated HMG Box (TOX) transcription factor. Initial network analysis identified TOX as one of the most differentially connected TFs expressed by memory and exhausted T cells, suggesting a possible important role in exhaustion [20]. This was later clarified by work showing that TOX could be the master regulator driving an exhaustion phenotype marked by the upregulation of inhibitory receptors, decreased cytokine production and epigenetic remodelling in chronic infection or in a tumour setting [23–27]. TOX is required for the formation of exhausted CD8+ T cells via chromatin remodelling and alteration of gene expression profiles. Additionally, TOX promotes the expression of genes that are often associated with exhaustion, including the expression of inhibitory receptors such as PD-1, TIM-3 and LAG-3 and transcription factors EOMES, TCF-1 and CD38. TOX expression is regulated by NFAT, a key regulator of T-cell exhaustion and dysfunction (discussed above).
While the expression profiles and gene-regulatory networks of these transcription factors have been well studied in the context of exhaustion (summarized in Table 1), how these expression patterns ought to be used to define exhaustion still needs clarification. It has been known for a long time now that a spectrum of exhausted T cells will exist, from naïve, undifferentiated cells to terminal differentiation cells. The expression of T-bet and EOMES was originally used to define subpopulations within the exhausted cells. A population of proliferation-competent progenitors was defined as TbethiEomeslo and terminal effectors as TbetloEomeshi [19]. Recent work from Beltra et al. [28] has fine-tuned the transcription factor-based definition of exhaustion states. Now, exhaustion is defined as a spectrum of phenotypes with four developmental subsets forming depending on the state of the TME and/or peripheral tissue. These subsets consist of (1) TEXprog1, which are quiescent lymphoid-tissue resident non-proliferative progenitor cells, have high TCF-1 expression, are slowly dividing and have good persistence; (2) TEXprog2, which are TCF1+, highly proliferative, activated progenitor cells with good persistence; (3) TEXint comprising an intermediate population with some effector activity and migratory capacity, but no TCF-1 expression and (4) a terminal population, TEXterm, that is more cytotoxic but non-recirculating. This scheme also clarified how the other transcription factors change in the four developmental stages of exhaustion. For example, T-bet is a major regulator of the TEXint population, with TOX expression negatively correlated with T-bet expression. TOX expression decreased as T-bet expression increased and cells progressed from progenitor cells to intermediate cells. TOX expression, however, increased in terminal cells, leading to a decrease in the expression of T-bet. EOMES, on the other hand, was expressed by the TEXprog1 but downregulated in the TEXprog2 and TEXint subsets. EOMES, however, rebounded back to high expression in the TEXterm subset [28]. The levels of expression of transcription factors are therefore helpful for defining distinct states of exhaustion.
Table 1.
Summary of transcription factors expression associated with effector, progenitor and terminally exhausted T cells
| Transcription factor | Effector T cell | Progenitor exhausted T cell | Terminally exhausted T cell | References |
|---|---|---|---|---|
| TCF-1 | High | High | Low | [8, 22] |
| Ratio of T-bet and EOMES | More T-bet | More T-bet | More EOMES | [18, 19, 21] |
| BATFa | Complexed with IRF4 promotes effector function | High | High | [11, 15, 29, 30, 31, 32] |
| NFAT | Heterodimer with AP-1 | Unclear | NFAT homodimer | [14] |
| PRDM1 | High | Low | High | [30, 33] |
| NR4A | Low | High | High | [17, 24] |
| TOX | Low | High | High | [23, 25, 26, 27] |
Sustained expression of inhibitory receptors
The identification of inhibitory receptors, including PD-1, CTLA-4 and TIM-3, as ‘exhaustion markers’ was one of the first key definitions of T-cell exhaustion [34]. It is thought that in the continuous presence of antigens, inhibitory receptors affect exhaustion by dampening the activation of antigen-specific T cells. PD-1 is the most-studied molecule in the context of exhaustion. Normally in T cells, PD-1 expression increases in response to TCR stimulation. In the context of exhaustion, however, there is constitutive PD-1 expression and PD-L1 engagement, inhibiting CD8+ T-cell function. Reagents that block the PD-1/PD-L1 interaction, e.g. anti-PD-1 and anti-PD-L1 antibodies, induce an anti-tumour response via the reinvigoration and expansion of CD8+ cell populations and by increasing their cytotoxic activity [35]. In addition to PD-1, in a chronic infection with viruses, antigen-specific CD8+ T cells in both animals and humans will co-express other inhibitory receptors including LAG-3, CD244 (2B4), CD160, TIM-3 and CTLA-4 [34]. In the LCMV model, exhausted T cells expressed a number of these inhibitory receptors and the severity of the infection correlated with both the levels and the number of different inhibitory receptors expressed per cell [36]. SLAMF6 has also been identified as a marker of ‘progenitor exhausted’ cells, and TIM-3 as a marker on ‘terminally exhausted’ cells, whereas PD-1 is found on both subsets, with increased expression on the terminally exhausted cells [33]. Expression of inhibitory receptors on exhausted T cells is attributed to the master regulator of exhaustion TOX, which increases chromatin accessibility at the promoters of these genes. Importantly, TOX is required for the continuous PD-1 expression by reducing its degradation and promoting its recycling back to the cell surface [37]. Expression of inhibitory receptors in exhaustion is believed to occur for all lymphocytes, with NK cells and B cells also upregulating PD-1 in their exhausted states. Other receptors unique to each cell type are also present, such as KIRs in NK cells and CD11c in B cells (reviewed in detail by Roe [38]).
The functions of inhibitory receptors in exhausted T cells are poorly understood. These receptors are not exclusively found on exhausted cells, with various receptors playing different physiological roles during canonical T-cell activation. In the ‘tide model’ of acute T-cell activation [39], inhibitory receptors, including PD-1 and CTLA-4, are upregulated in order to counteract stimulation through the TCR and co-stimulatory receptors such as CD28, preventing excessive responses. It could be argued that this explains the pattern of inhibitory receptor expression in chronically stimulated exhausted T cells. The extra stimulation occurring in disease contexts may take the process too far, with increased inhibitory receptor signalling resulting in the dysfunction of exhausted T cells. Although PD-1 is not required for exhaustion to be established in LCMV-infected mice, its absence produces more severe exhaustion [40]. This indicates that PD-1 may still be functioning in its canonical role of preventing over-stimulation of cells even in exhausted cells. Alternatively, expression of the inhibitory receptors could merely reflect underlying transcriptional and epigenetic changes and have no exhaustion-specific function. This is supported by the fact that PD-1 blockade appears to have a minimal effect on the TIM-3+PD-1+ terminally exhausted-cell population, indicating that PD-1 is not actively inhibiting the cytotoxic function or proliferation of these cells [33], although the presence of other co-inhibitory receptors, such as LAG-3 and TIGIT, may restrict the reinvigoration effect of only targeting PD-1. Co-blockade of both LAG-3 and PD-1 has a synergistic effect on LCMV-induced exhaustion, enabling greater T-cell function and clearance of virus [36]. Thus, inhibitory signalling networks from multiple inhibitory receptors acting non-redundantly may be resulting in T-cell exhaustion and dysfunction, and could be limiting the effects of targeting only one receptor in checkpoint blockade. Ultimately, the role of inhibitory receptors in exhausted T cells is an area which obviously requires more investigation, to determine whether inhibitory receptors expressed on exhausted cells are functional or simply a by-product of underlying transcriptional changes.
Loss of effector function
The early studies mainly defined exhaustion as the inability of cells to produce effector molecules. More than two decades ago, in a seminal study, Zajac et al. [2] identified T cells in chronic viral infections that persist but do not produce IFN-γ. Subsequently it was suggested that as T cells become exhausted they sequentially reduce the production of IL-2 and then TNF, followed by the complete loss of IFN-γ [41–43]. More recently, it has become clear that the way exhausted T cells lose their effector function is not completely hierarchical. In fact, exhausted T cells should not be viewed as cells that are devoid of effector function—they can produce inflammatory cytokines and granzymes and are important for maintaining some control over chronic infections and tumours. The heterogeneity of exhausted cells comes into play here once again. In the four-stage hierarchical developmental pathway model of Beltra et al., it became clear that precursor exhausted cells that express PD-1 have reduced effector molecule expression but the intermediate population (TCF-1−/T-bethigh) downregulates PD-1 expression, which coincides with their regaining the ability to proliferate and produce effector molecules. The expression of TCF-1 is thought to be important here as it promotes the expression of an array of key effector function-associated transcription regulators, including Foxo1, Zeb2, Id3 and EOMES [44]. In addition, exhausted CD8+ T cells are also poor responders to homeostatic cytokines such as IL-7 and IL-15, although this feature is rarely used to define exhausted T cells [45].
Altered metabolic activity
In the process of becoming exhausted, T cells alter their metabolic activity. In the early stages, glycolysis is down-regulated, which is attributed to the expression of inhibitory receptors [46]. This has been studied mainly in the context of PD-1 signalling and it is known that the cytosolic tail of PD-1, which contains an immunotyrosine inhibitory motif and an immunotyrosine switch motif, recruits the phosphatase SHP-2, which antagonizes signal transduction by the TCR. One pathway affected is signalling through the PI3K/AKT/mTORC1 axis which, when reduced, blocks glucose uptake by downregulating Glut1 expression, and glycolysis by suppressing the expression of the key glycolytic enzyme, hexokinase 2 [47, 48]. In the absence of glycolysis, it is proposed that exhausted T cells rely on fatty acid oxidation [46]. Exhausted tumour infiltrating T cells also have a marked loss of mitochondrial mass and function [46, 49]. This is mainly caused by loss of PPAR-gamma co-activator 1α (PGC1α), which is responsible for mitochondrial biogenesis [50]. PGC1α is repressed by the transcription factor Blimp-1 which is active under continuous TCR stimulation and hypoxic conditions [51]. Overall, the metabolic alterations of exhausted T cells are yet to be exhaustively characterized and for now, the known changes are not used to define exhaustion. It could well be that the changes are wholly secondary to the sustained expression of inhibitory receptors.
The epigenetic status of exhausted T cells
Studies in murine chronic infection and tumour models have shown that epigenetic rewiring is a key part of the exhaustion differentiation programme, underlying the archetypal transcriptional network changes discussed above. It is the extensive epigenetic changes or ‘scars’ that exhausted cells carry which leaves them unable to acquire functional potential even after the antigen is eliminated. Antigen-specific exhausted T cells in the LCMV model were found to have a net increase in chromatin accessibility, particularly at enhancer sites for exhaustion-associated genes, including Havcr2 and Pdcd1 [52]. These changes were specific for chronically stimulated cells, with unique epigenetic alterations producing ∼6000 differentially accessible genetic loci compared with acutely stimulated cells [30, 53, 54], further reinforcing the differences in the differentiation of exhausted versus effector or memory cells. TOX had a key role in this reprogramming, with removal of TOX increasing chromatin accessibility at effector-related genes in LCMV-specific T cells, via the recruitment of a variety of chromatin remodelling proteins [23]. De novo DNA methylation of effector genes by Dnmt3a, in particular, is implicated as a regulator of exhaustion, with new DNA methylation at Tcf7, Ifng and Myc loci being linked to the differentiation of the exhausted cells: deletion of Dnmt3a resulted in reduced cell dysfunction and heightened proliferation [55].
Epigenetic differences between the stem-like and terminally exhausted subsets in LCMV-specific murine T cells have also been identified. Stem-like cells had chromatin accessibility regions (ChARs) at memory-associated genes (Il2, Tcf7) and co-stimulatory receptors (Icos, Cd28), whereas for the terminally exhausted subset, inhibitory receptors (Pdcd1, Havcr2) and cytotoxic effector genes (Gzmb) had increased chromatin accessibility [23, 30]. Similar differences were identified in human tumour-specific exhausted cells, suggesting a conserved epigenetic programme exists across exhausted cells [33]. Crucially, these alterations in chromatin accessibility were reflected in the transcriptomes of these cells [23, 30, 33], linking chromatin remodelling with the phenotypic changes discussed above.
There is great therapeutic interest in understanding the epigenetic plasticity of exhausted T cells as the unique epigenetic reprogramming of exhausted T cells may present a barrier to the reinvigoration of T cells by immune checkpoint blockade (see review by Dolina et al. [56] for more on reversal of T-cell exhaustion). ATAC-seq of exhausted murine tumour-specific T cells following anti-PD-1 treatment exhibited only a small change in ChAR distribution relative to non-treated cells, with limited changes in the associated transcriptional networks [54]. Work in LCMV mouse models indicated that there is an irreversible epigenetic transition following initial reversible transitions in the exhaustion spectrum suggesting that, beyond a certain point, cells cannot be fully restored to an effector phenotype [53]. However, inhibition of DNA methylation or use of DNA demethylating agents in exhausted cells prior to PD-1 blockade boosted the reinvigoration of exhausted cells, indicated by the increased proliferation and effector function of LCMV-specific T cells [55]. Although immune checkpoint blockade by itself may not overcome the epigenetic barrier presented by exhausted T cells, targeting chromatin remodelling could improve the therapeutic outcome of checkpoint blockade. Recent work by Ford et al. [57] shows that even in terminally exhausted cells, large portions of DNA contain open structures but gene expression from these regions require strong co-stimulation. Additionally, the hypoxic environment of the TME further contributed to the impaired gene expression. Therefore, restoring oxygen availability or improving co-stimulation could be an alternative way to help reinvigorating exhausted cells that have epigenome markers that are indicative of terminal exhaustion [57].
Although not commonly used as a marker of exhaustion, the epigenetic programmes underlying the transcriptional and phenotypic changes observed are unique to this differentiation pathway. While whole epigenomes are heterogeneous across exhausted-cell populations, epigenetic events including greater chromatin accessibility and de novo DNA methylation events at specific loci, such as Pdcd1, are likely to be useful for distinguishing exhausted cells from other T-cell populations.
To summarize, most studies use the inhibitory receptor expression, effector functions and, less commonly, transcriptional states to define the exhausted T-cell phenotype (summarized in Fig. 1). The expression of inhibitory receptors is the most used definition, as it is closely tied to other features of exhaustion (e.g. the epigenetic and metabolic states) [58]. However, these molecules are upregulated during the normal course of T-cell stimulation, and so inhibitory receptor-based definitions of exhausted T cells will be unreliable, and we argue that this alone cannot be used to adequately define cells in this state. Effector functions are also commonly used but the effector behaviour of exhausted cells is indistinguishable from that of anergic cells. The expression of transcription factors can help to define the exhausted state, with the expression of TOX being the most helpful marker. Given these difficulties and the developmental heterogeneity of exhausted cells, great care must be exercised in identifying these important cells, especially when working with T cells generated in vitro, which we will now discuss in detail.
Figure 1.
The most common properties used to define exhausted T cells. The expression of inhibitory receptors, their effector functions, expression of specific transcription factors, metabolic activity and their epigenetic status are used to define exhaustion of T cells.
Approaches to study/generate exhausted T cells
Isolation of exhausted cells from mouse models and human tissue
In vivo/ex vivo approaches have yielded fundamental insights into the requirements for the induction and progression of T-cell exhaustion (i.e. persistent antigen exposure).
In vivo mouse models are most employed to study T-cell exhaustion/hyporesponsiveness. Exhaustion was first characterized, and continues to be studied, by infecting mice with either LCMV clone 13 or the LCMV-D (DOCILE) strains, which both establish a persistent infection at a high titre [1, 2, 15, 18, 20, 23, 36, 42, 59, 60–64]. Experiments will typically involve analysing the function and phenotype of adoptively transferred transgenic antigen-specific T cells (e.g. LCMV P14) taken from the spleen/lymph node/tissue of infected mice at different time points. Caveats of this approach are that it takes a substantial time commitment to produce exhausted cells in mice (∼30 days; [65]) and yields limited numbers of cells for experimentation. To illustrate this, one study using the LCMV challenge model to isolate exhausted T cells reports using 10 mice for a single scRNA-seq experiment [66]. Despite this, mouse models provide the flexibility of performing perturbation experiments to characterize gene functions but the translation from mouse to humans remains, of course, a challenge in many cases.
Isolating exhausted cells directly from human tissue is also a commonly used approach. Exhausted T cells in humans were first identified and studied from patients with chronic viral infections [i.e. human immunodeficiency virus-1 (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) [16, 67–77]]. Around the same time, exhausted tumour infiltrating T cells (defined at the time by inhibitory receptor upregulation and reduced cytokine production when stimulated ex vivo) were isolated, and continue to be identified, from a variety of tumours (e.g. human metastatic melanoma tissue, ovarian cancer, non-small cell carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, chronic lymphocytic leukaemia and chronic myeloid leukaemia [78–93]), subsequently leading researchers to establish several mouse tumour models to study exhaustion [65, 90, 94, 95]. Studying human tissue relies on obtaining patient blood from virus-infected individuals or tumour explants followed by isolation of immune cells using a Ficoll-Paque gradient and subsequent experimentation with known viral or tumour antigen-specific T cells (further isolated or stained via MHC tetramers) [84]. For tissue, this requires performing mechanical dissection, enzymatic digestion and straining to isolate single-cell suspensions for subsequent analysis. Typically experiments involve surface profiling of tetramer-labelled T cells (e.g. for PD-1, TIM-3, LAG-3) from PBMCs or single-cell suspensions of tissue, measurements of cytokine production (i.e. IFN-γ, TNF-α, IL-2) and proliferation assays. To stimulate isolated cells ex vivo, researchers pulse PBMCs with antigens over several days, and subsequently analyse tetramer+ T cells for functional outputs, or in the case of tissue samples, isolate T cells via flow cytometry or CD3 microbeads and then perform experiments [96]. Most studies have not examined exhaustion per se but rather hyporesponsive T cells exhibiting reduced cytokine production and altered surface profiles. However, more recent efforts have performed single-cell RNA-seq and mass cytometry on T cells isolated from patient tumour tissue, providing more extensive transcriptional and surface descriptions of exhausted T cells [92, 96–100].
Table 2 summarizes the approaches and caveats of current isolation/experimentation techniques in mice and human Tex cells. A major caveat of these isolation approaches is that it is difficult to assign cause and effect for driving phenotypes in general. While informative of the existing state of T cells within a patient, the approaches to isolate cells from humans cannot be applied to mechanistic studies that give rise to exhaustion owing to the limited number of cells isolated from patients, and the inability to track their differentiation/activity over time in situ. Isolation-based approaches are also dependent on access to patient cells/tissue, which can be a barrier to experimentation.
Table 2.
Summary of approaches and caveats of current isolation/experimentation techniques in mice and human Tex cells
| Tex isolated from infected/tumour model mice | Tex isolated from human virally infected/tumour tissue | |
|---|---|---|
| Method of isolation | Adoptive transfer of T cells with known antigen specificity first isolated from CD45.1 congenic mice into virally infected/tumour CD45.2 mouse models. CD45.1+ T cells are then re-isolated from the spleen/blood/tissue of CD45.2+ mice and phenotypically/functionally characterized. | Either bulk T cells or T cells of known antigen specificity (isolated using MHC tetramers, which requires prior knowledge of T-cell antigen specificity) are isolated from single-cell suspensions of mechanically digested tissue explants. T cells are typically considered exhausted based on surface markers (i.e. PD-1+). |
| Time to isolate Tex cells | Up to ∼30 days after transfer of T cells into a liver tumour mouse model [84]. | Obtained immediately from tissue. |
| Isolation and experimentation of Tex cells from virally infected mice will occur between 8 and 30 days post-infection. | ||
| Cell yields for future testing | Low. For clone 13-based induction of exhaustion, typically, <1 × 106 P14 T cells are transferred into, and re-isolated from, an infected mouse. In tumour-based models of exhaustion more cells may be transferred. For example, 2 × 106 T cells of known antigen specific (OT-1 T cells that recognize OVA peptide) were used in an OVA-expressing melanoma model [85]. Owing to limited cell number, researchers may need to pool cells from several mice to perform both functional and ‘omic’-based approaches. | Limited. Very few T cells of known antigen specificity that are additionally PD-1+ will be obtained. This makes functional and/or ‘omic’-based characterization difficult. More recent studies will sort T cells from digested tissue directly for single-cell analysis. |
| Access to samples | High as many institutes with an immunology focus have access to a mouse house or mouse studies. | Low and variable. Will likely require a medical collaborator from specific hospitals to obtain tissue, and tissue samples will likely be received irregularly. |
| Mechanistic studies | Possible as genetically modified T cells can be adoptively transferred and tracked in situ through re-isolation of T cells from spleen/tissue/blood of infected mice. | Very difficult/not possible as the establishment of Tex cannot be tracked in situ within human tissue explants. However, it may be possible to follow the establishment of human Tex via transfer of T cells of known antigen specificity into patient-derived organoids. |
| Assigning cause–effect | Difficult to assign cause–effect as it is challenging to parse out the many signals derived from different cell–cell interactions and the microenvironment. | Not possible. Analysis of Tex isolated from human tissue only provides a snapshot of their state and influence of the local microenvironment. |
To overcome this, several labs have turned to in vitro approaches to generate large numbers of mouse and human exhausted T cells within shorter time periods (i.e. 5–14 days). Although successful in recapitulating the hyporesponsiveness of T cells as well as similarities in surface protein expression profile, reduced cytokine production and altered transcription factor activity, it remains unclear how well this captures the total and/or diverse transcriptional and epigenetic landscape of exhausted T cells in vivo [101–103], particularly as microenvironmental signals, and the diversity of cell–cell interactions with other immune cells [e.g. myeloid-derived suppressor cells, Tregs, cancer-associated fibroblasts, tumour-associated macrophages (TAMs)], are known to influence T-cell exhaustion, with their specific contributions still being parsed out [46, 49, 57, 104–107]. That being said, in vitro approaches are easy to establish and have controllable complexity, therefore are possibly becoming the go-to approach in the future at least for large-scale and systematic dissection of key factors driving exhaustion. Below, we will discuss in detail how these new in vitro approaches for T-cell exhaustion are being used in the field.
In vitro approaches to generate exhausted T cells (antibody-based stimulation)
Increasingly frequent use is being made of the continual activation of T cells using anti-CD3 +/− anti-CD28 (on plates or beads) to achieve a proxy exhaustion state owing to its ease and scalability. Balkhi et al. [108] were the first to produce exhausted T cells in vitro using cell-activating beads. Peripheral human CD4+ and CD8+ T cells were stimulated with anti-CD3/CD28 beads for 8 days, provoking the expression of increasing numbers of exhaustion markers, i.e. reduced cytokine production, upregulation of PD-1/LAG-3/TIM-3 and reduced killing capabilities [108]. Important caveats of this study were that there was no deep transcriptional, epigenetic or metabolic analysis of the cells relative to exhausted cells taken from in vivo models, making it difficult to judge how well they were able to recapitulate in vivo exhaustion. Furthermore, it is uncertain whether removing the beads after day 8 would have led to reversal of their reduced functional state, and therefore unclear whether the cells were truly exhausted. Extending this approach, Corselli et al. [109] performed a more extensive examination of the surface and transcriptional changes that occur with T cells stimulated for 14 days with anti-CD3/CD28 beads and IL-2 [109]. Changes in the expression of 38 surface proteins were followed using AbSeq, which uses multiplexed amplification reactions based on antibodies tagged with unique sequence identifiers, and targeted RNA-seq analysis of ∼400 genes. Future studies that include comparisons with ex vivo exhausted T cells isolated in vivo experiments would greatly extend this powerful approach.
Two studies have examined the metabolic changes that accompany T-cell exhaustion induced by antigen-expressing cells/anti-CD3-coated culture plates or anti-CD3/CD28 beads for persistent stimulation. The first study, by Verdhana et al. found that chronic T-cell stimulation induced in vitro invoked mitochondrial dysfunction via increased reactive oxygen species (ROS)-mediated inactivation of the mitochondrial electron transport chain. In their experiments, Verdhana et al. re-stimulated mouse T cells that had been pre-activated for 48 h with anti-CD3/CD28-coated plates, with either an OVA-expressing B16–F10 melanoma cell line or anti-CD3-coated plates for an additional 8 days [110]. Both approaches recapitulated classic exhaustion markers in the manner of Balkhi et al., but not anergic ones, allowing a deep analysis of the role metabolism plays in exhaustion. Interestingly, in contrast to the experiments of Balkhi et al. with human T cells, Verdhana et al. found that plastic-immobilized anti-CD3 was sufficient to drive exhaustion per se. The reasons for these differences are unclear, but Vardhana et al. were able to benchmark their in vitro-generated, exhausted cells against LCMV clone 13 isolated T cells, showing that they exhibited similar surface marker and cytokine production changes, and similar transcriptional profiles. In the second study, Delgoffe and colleagues examined the impact of microenvironmental signals (i.e. hypoxia; 1.5% oxygen) on T-cell exhaustion during persistent stimulation of pre-activated (i.e. CD44+) T cells with anti-CD3/CD28 beads under hypoxic conditions for 5 days [51]. Compared with cells stimulated under normoxic conditions, they observed enhanced expression of exhaustion markers (i.e. PD-1, TIM-3, LAG-3, TOX) and reduced cytokine production, which persisted for 5 more days after removal of stimulation. Transcriptional analysis showed that their in vitro-produced, hypoxic, continuously stimulated cells were better mimics of terminally exhausted T cells from the B16 melanoma mouse model [33] than the cells produced under normoxic conditions, suggesting that hypoxia exacerbates of accelerates exhaustion. Like Verdhana et al., Delgoffe et al. demonstrated mitochondrial dysfunction and increased ROS production, but went further by showing that the ROS build up was promoted by the repression of transcriptional programmes that normally control ROS production. This led to the suppression of phosphatase activity (ROS being a known inhibitor of phosphatase activity [111]), reinforcing the chronic stimulation of the T cells. Nevertheless, the authors noted that their transcriptional data were not wholly supportive of the notion that they had created ‘real’ exhausted T cells, as the in vitro cell-derived transcriptome did not match that of TILs from the B16 melanoma model. However, these experiments highlighted the power of in vitro approaches to understanding drivers of exhaustion beyond antigen exposure. Notably, Delgoffe et al. switched from using the B16 melanoma cell line to induce exhaustion in T cells and used anti-CD3/CD28 beads instead, arguing that this avoided the confounding effects of other signals produced by tumour cells under hypoxic stress. Future experiments can begin to elucidate the additional role, if any, of these other signals.
In more recent work, Belk et al. [102] developed an in vitro system to model chronic antigen stimulation-induced T-cell exhaustion in which T cells were first stimulated for 2 days using anti-CD3/anti-CD28-coated beads and IL-2, and then continuously for another 8 days with anti-CD3 antibody-coated beads only and IL-2 [102]. These cells produced less cytokine over time and acquired an epigenetic profile like that of terminal exhausted CD8+ T cells, which the authors defined as a proxy exhaustion state. Owing to the scalability of their approach, producing up to 108 cells/experiment, Belk et al. [102] were able to perform a genome-wide knockout screen of exhaustion. They compared gRNA frequencies at the end of chronic stimulation versus those in cells at the end of an acute stimulation comprising treatment with IL-2 alone rather than anti-CD3 antibodies and IL-2. In this way, Belk et al. [102] were able to identify candidate regulators of this proxy-exhausted state as genes whose knockout led to better proliferation of the chronically stimulated cells. Among the ‘hits’ were chromatin modifiers including Arid1a, Smarcc1 and Smarcc2. The gene hits were then tested in mouse cancer models, which confirmed that CD8+ T cells lacking expression of these genes exhibited better proliferative responses to the tumours. Importantly, Arid1a-deficient CD8 T cells had open a region of chromatin around the gene encoding IFN-γ and less accessible regions around classical exhaustion markers such as Pdcd1, Entpd1 (CD39) and Tox. While this study established a powerful new approach for identifying markers of exhaustion, several limitations/caveats should be noted. First, chronically stimulating cells with beads alone cannot, of course, wholly recapitulate the complex process by which exhaustion develops in a chronic infection or a cancer setting where multiple cell types, receptor-ligand interactions and (as discussed above) microenvironmental signals contribute to the outcome. The screen by Belk et al. could not identify classical surface markers of exhaustion such as PD-1, for example, presumably because their ligands were not engaged in the assay system. Second, as the exhausted state was established after chronic stimulation without resting the cells, it is unclear whether the epigenetic state of the cells induced by the gene deletions was stable or not. Lastly, stimulation with anti-CD3 antibodies only could have invoked an anergic state rather than an exhausted one, a possibility that was not examined. Notwithstanding all of this, the animal experiments confirmed that in the absence of Arid1a, CD8+ T cells retain proliferative and cytotoxic function in vivo and are better at tumour clearance.
Overall, the use of anti-CD3/CD28 antibodies to chronically stimulate T cells appears to be a viable, scalable approach to producing T cells with many exhaustion-like features. It will be necessary, however, to carefully characterize and compare the functional activity and transcriptional profiles of the cells at the end of stimulation regimes, with published in vivo data on exhausted and anergic T cells. It needs also to be noted that chronic stimulation of T cells can induce cell apoptosis/death, and so it is important that appropriate controls and/or approaches to remove such cells from the analysis are undertaken.
In vitro (antigen/target cell-based stimulation)
To better mimic physiological T-cell activation, Zhao et al. [101] stimulated OT-1-specific CD8+ mouse T cells with antigen. They incubated the cells with OVA [257–264] peptide for 5 days along with the cytokines IL-7 and IL-15. Cells stimulated for 5 days produced less IFN-γ and IL-2, minimal TNF-α, increased expression of exhaustion surface markers and exhibited reduced killing capacity. Looking beyond functional readouts, Zhao et al. observed transcription factor expression and methylation patterns typical of terminally exhausted T cells, i.e. increased TOX and T-bet expression, and downregulation of TCF-1, coinciding with increased methylation [8, 25]. Furthermore, the transcriptional activity of their in vitro exhausted T cells matched that of T cells isolated at day 30 from LCMV clone 13 infected mice. They could also rule out the induction of anergy through comparison of transcriptional data to in vitro anergy models [112]. Of note, Zhao et al. showed that 0.1% of the CD8+ population purified from PBMCs comprised CD11b+CD11c+ dendritic cells, which would result in a 1:1000 ratio of target cell to T cells, which is slightly lower than that in vivo [113, 114]. In these experiments, therefore, there will likely be contributions from both T-cell:T-cell and DC:T-cell interactions to the exhausted state, with the former dominating. Nah and Seong [115] used a similar approach to study the role of transcription factors during T-cell exhaustion in vitro, expanding the method to include retrovirally induced genetic modifications through viral transduction on Day 1 of the stimulation.
Recently, Trefny et al. performed a targeted, pooled CRISPR screen on in vitro exhausted T cells to identify Snx9 as a key regulator of exhaustion. To create exhausted T cells in vitro, they used repeated stimulation of NY-ESO-1-specific CD8+ T cells (transduced with the 1G4-TCR; [116]) via an irradiated T2 tumour cell line pulsed with NY-ESO-1 antigen over 12 days (adding freshly pulsed target cells every 3 days). A suite of markers was used as validation, including increased PD-1 expression, reduced cytokine production (IFN-γ, TNF-α), less specific-killing, reduced degranulation and less proliferation [103]. Further validation came with gene set enrichment analysis, which showed that their in vitro-generated exhausted T cells resembled those from exhausted TILs taken from an ‘atlas’ of cancer associated T cells [117]. Importantly, their exhausted cells maintained high PD-1 expression and reduced degranulation 7 days after removing the activation stimulus, strengthening the case for having generated bona fide exhausted T cells. To perform targeted CRISPR screens, Trefny et al. transduced CD8+ T cells with a vector expressing gRNA+Cas9+mCherry alongside the 1G4-TCR, sorted for these cells, and then performed their stimulation regime, with an additional 4-h stimulation step at the end to identify exhausted T cells (based on low/no degranulation). This approach revealed that Snx9 modulates the calcium response, subsequent transcription factor activity (i.e. NFAT), metabolic activity. In the absence of Snx9, IFN-γ production by T cells was increased.
The use of peptide antigens and irradiated target cells pulsed with peptides is proving useful for generating in vitro exhausted T cells. This approach seems to capture the core exhaustion state, yields ∼×10 more cells than that seeded for experimentation [101] and enables downstream analysis of T cells without the need for sorting, as would occur for heterotypic live cell interactions. Of note, extensive use of anti-CD3/CD28 antibodies and peptides for pulsing cells is expensive. An alternative and cheaper approach is the use of irradiated target cells genetically modified to stably express single-chain trimers presenting peptides of interest [118]. This may also simplify the protocol of Trefny et al., as there would be no need to add freshly pulsed target cells every 3 days.
Future approaches to study T-cell exhaustion
With the advent of in vitro approaches for generating exhausted T cells and ease of genetically manipulating primary T cells (see Ref. [119] for a review on improvements on methods to manipulate primary T cells), the possibility of performing systematic, large-scale analyses of the genetic regulators of exhaustion is emerging. However, it will continue to be necessary to validate findings in suitable mouse models. Taking advantage of their convenience and scalability, we can expect the systematic analysis of in vitro exhaustion models to benefit from the ‘dialing in’ of complexity alongside maintaining persistent antigen exposure. This will include adding paracrine signals (e.g. growth factors, cytokines, metabolites), altered microenvironments, e.g. hypoxia, pH acidification, 2D versus 3D settings and extracellular matrix components, live target cells that may include genetic modifications to surface proteins/secreted proteins of interest and/or the additional cell types present in tissues alongside exhausted T cells. More advanced systems can include organoid culture systems, organ/tumour-on-a-chip and the ex vivo maintenance of patient-derived explants. Inevitably, with each increase in system complexity, controls will become even more important. For example, each different target cell incorporated alongside exhausted T cells will generate contact-dependent and independent signals that will need to be deconvoluted. Below, we discuss how future in vitro studies on T-cell exhaustion may be undertaken.
Additional paracrine signals and cell–cell interactions
The inflammatory milieu of chronically infected tissues or tumours has an important role in regulating CD8+ T-cell responses [9, 120–122]. Although not sufficient to drive exhaustion alone, it very likely influences the progression, kinetics and ‘depth’ of the exhausted state. The inflammatory milieu comprises paracrine signals (e.g. cytokines, metabolites) and contact-mediated interactions (e.g. PD-1 engagement with PD-L1). An important example of the former is IL-10, which is typically elevated in chronic HBV, HCV and HIV [123], and whose blockade enhances T-cell responses during LCMV clone 13 infections [124]. The cooperation of IL-10 and Tregs (along with IL-35) is suggested to promote T-cell exhaustion in murine and human non-small cell lung cancer [125]. Metabolic influences on T-cell responses, typically stemming from tumour/T-cell competition and/or other immune cell activity, include glucose and amino acid (e.g. arginine and tryptophan) depletion, lactate build up, altered lipid availability and ion availability [126–130]. Many metabolic changes are yet to be directly linked to exhaustion but are worth examining given their known impact on T-cell responses. The roles of other extracellular signals thought to influence exhaustion are reviewed elsewhere [9, 129]. In the immediate future, we expect the influence of cytokines, metabolites and their combinations to be tested in vitro alongside anti-CD3/CD28 beads or target cell line-mediated stimulation of CD8+ T cells. It would, of course, be useful to measure the levels of these extracellular signals in physiological settings (or at least perform titrations) to appropriately gauge their influence, if any. Such changes may not always be relevant in vivo owing to the adaptability of cells, e.g. with metabolite availability [131]. Nonetheless, such screens will be useful for identifying the most important potential mediators of exhaustion.
It is now known that other tumour-associated immune cells can modulate the exhausted phenotype. For example, Tregs, MDSCs and TAMs are commonly found in tumours and all have been implicated in helping drive T-cell exhaustion [132]. Although less well-studied, these cells are being increasingly implicated in chronic viral infections [133]. Typically, studies that characterize the impact of other immune cells on T-cell exhaustion are performed using mouse models or human tissue ex vivo, where it is difficult to assay their contributions to exhaustion, e.g. whether their influence is contact-dependent/independent, and to assign causality. Co-culturing these cells with CD8+ T cells, ex vivo/in vitro systems will therefore likely be helpful. As an example, Krummel and colleagues have shown that the direct interaction of CD8+ T cells with TAMs, one of the most abundant antigen-presenting cells in the TME [134–136], was, in part, responsible for driving exhaustion in mouse tumour models. Interestingly, the ex vivo/in vitro co-culture of TAMs and T cells isolated from mice revealed that the T cells formed stable interactions with TAMs and more so than with bone-marrow-derived dendritic cells, leading to weak but constitutive signalling. Building additional complexity into their system, they examined the impact of hypoxia, with the data suggesting that TAMs, especially, may prime T cells for exhaustion under hypoxic conditions. However, the only fraction of PD-1+ cells was used to support these observations, and deeper analyses are needed. Nevertheless, the value of increasingly complex in vitro approaches for parsing out potential drivers of exhaustion was established. One issue, however, is that the isolation and expansion of these cell types remain a significant barrier, especially from human tissue, although Tregs can be isolated from PBMCs, recognizing that these might not completely resemble Tregs from tumours, and there is considerable effort going into the development of methods for isolating TAMs and MDSCs for use in vitro [137–139]. Prior to performing co-culture experiments, it will be important to characterize target cells of interest to an appropriate standard as in the case, e.g. of MDSCs [140].
3D spheroid and organoid culture systems
Since the early 1900s, in vitro cellular experiments have mostly been performed in 2D [141]. While this has its merits, i.e. simplicity, accessibility, affordability and suitability for most if not all forms of microscopy, it fails to capture physiological tissue structure, e.g. the 3D shape and polarization of cells, the organization of tissue, interactions with the extracellular matrix, the diversity of cell–cell interactions and the asymmetric signals and nutrient availability characteristic of tissue [142, 143]. 3D models are therefore being developed for the analysis of cell behaviour and function, which broadly fall into two categories: spheroids and organoids. Spheroids are 3D cell aggregates generated from a single cell type, typically adherent cell lines but also cells from patients, with added complexity achievable with the incorporation of additional cell types. Spheroids often form without the need for a scaffold, being inducible using hanging-drop or suspension culture approaches. Large spheroids of several hundred micrometres in diameter tend to induce oxygen and nutrient gradients, with their protein and gene profiles often resembling in vivo profiles [144, 145]. As a relevant and recent example of their use to study T-cell behaviour, Ou et al. [146] characterized T-cell infiltration and activity in tumour spheroids derived from melanoma cell lines. They added additional complexity by incorporating cancer-associated fibroblasts into the spheroids, noting their suppressive effect on T-cell infiltration and activation. Such systems, modified to incorporate antigen specificity, could be used to induce chronic stimulation and activation of T cells in a more solid tumour-like setting. Spheroids are well suited to high-throughput experimentation allowing, e.g. cytokine/metabolite screens to identify agents that alter exhaustion progression/reversion, but this is yet to be tried. Potential caveats include the fact that spheroids are nevertheless relatively simple structures that show some variability in production [147].
Organoid cultures offer a potentially more powerful 3D in vitro context for studying exhaustion. Organoids are self-organizing 3D structures established from stem cells or patient-derived tissue/tumour biopsies. Tumour-derived organoids are produced simply by mechanically or enzymatically digesting tumours into single-cell suspensions that are then incorporated into collagen matrices (e.g. Matrigel) to grow. Organoids mimic the architecture and function of the origin tissue and can comprise multiple cell lineages. Most importantly, organoids can be made to retain immune cell populations, as discussed below. Caveats include the need for customized and more complex culture conditions to ensure growth of a diverse population of cells, the issue of patient heterogeneity and cost. However, we expect the use of patient-derived T cells and autologous tumour organoids to become an extremely useful setting for creating and examining in vitro-generated exhausted T cells. Although challenging, this is now a realistic possibility, since it has now been shown that tumour-reactive T cells can be generated by culturing PBMCs and tumours derived from the same patient in air–liquid interface or microfluidic flow systems (see, e.g. [148]), in this way allowing for the development of antigen-driven exhaustion driven by paracrine signalling and cell–cell interactions in a highly physiological microenvironment (e.g. with appropriate oxygen gradients). Caveats of this approach are that there will likely be constraints on reproducibility owing to patient heterogeneity and non-standardized culture approaches, limited total numbers of T cells for analysis, i.e. scalability (although this could be circumvented by pre-stimulating T cells from PBMCs in vitro to expand them before their incorporation into the organoid culture) and the lack of a stable stromal compartment associated with the TME over the course of long-term culture [149], although this may be changing [150–152]. While the method is yet to be applied to the analysis of exhaustion per se, single-cell RNA-seq analysis has shown that day 7 patient-derived tumour organoids do express exhaustion markers, i.e. PD-1, LAG-3 and TIM-3, underlining the potential value of this approach [150].
In addition to tumours, viral infections can be studied in organoids, opening a path to studying T-cell exhaustion in chronic viral settings (i.e. HBV, HCV and HIV). For example, ex vivo HBV infections and viral replication were established by infecting patient-derived healthy liver organoids with either recombinant HBV or HBV-infected patient serum or using HBV-infected patient liver explants [153]. Liver organoids were generated by isolating, expanding and differentiating primary EpCAM+ bile-duct cells derived from liver biopsies into hepatocytes in vitro [154, 155]. The cells could be expanded and biobanked and were amenable to genetic modification. However, access to such models will likely remain low owing to the need for patient liver biopsies and the complicated cell culture procedures required. More recently, Ott and colleagues used a commercially available microfluidic chip to co-culture liver organoids with CD8+ T cells specific to a HCV-derived antigen that was isolated using tetramers and expanded using irradiated PBMCs [156]. The CD8+ cells were responsive to HCV antigen pulsed into the liver organoid system, indicating the promise of studying chronic T-cell activation in such a setting. Human tonsil organoids infected with HIV-1 have also been used to study the metabolic impact of HIV-1 infection on the induction and expansion of dysfunctional Tregs [157]. Although exhaustion was not the aim of this study, altered T-cell responses upon HIV-1 infection were observed, indicating the potential of the approach for studying exhaustion. Importantly, exhaustion-like markers expressed by tissue resident CD8+ T cells were observed among cells in the tonsils of HIV-infected patients, supporting the use of this tissue [158].
Organ/tumour-on-a-chip systems
Finally, ‘organ/tumour on a chip’ models are microfluidic cell culture devices that recapitulate 3D environments, tissue interfaces, vascular perfusion and nutrient and signal gradients. Such a system, recapitulating proliferating, quiescent and necrotic layers of solid tumours, was used to study exhaustion in NK cells. Ayuso et al. [159] placed the MCF7 breast cancer line embedded in a collagen gel into the central microchamber of the chip, with an endothelial lumen generated from an endothelial cell line, running through the collagen gel at one end, which could be used to perfuse NK cells, nutrients or other reagents. The method recapitulated tumour microenvironmental stresses, e.g. nutrient deprivation, pH changes and waste product accumulation, created as a gradient from the lumen, that enhanced ‘exhaustion-like’ features in NK cells analogous to those of T cells, e.g. upregulation of PD-1 and reduced expression of TNF-α. This example utilized a cell line. Combining the approach with patient-derived organoids could come close to mimicking solid tumours and their accompanying vasculature [160].
Conclusion
Exhaustion has been studied extensively using in vivo mouse models and T-cells isolated from tumours and/or chronically infected tissue. Owing to limitations in these approaches—to do mostly with scalability and throughput as discussed above—the field is moving towards in vitro approaches which are more likely to provide detailed molecular insights into how T-cell exhaustion is established and can be reversed (in Fig. 2). As this happens, it is important to note that the specific signatures of exhaustion will likely differ depending on the details of the cellular treatments, affecting the conclusions of these studies. It has been a common practice to use a set of genes and epigenetic signatures to define exhaustion and a number of studies have compared the exhaustion signatures of chronic infection models (mainly LCMV) versus cancer models as the basis for proposing that there exists a conserved and shared core regulatory network driving exhaustion [90, 95, 161]. In vitro-generated exhausted cells exhibit many of these key hallmarks of exhaustion, but it will be important to thoroughly characterize how well any given in vitro model captures the necessary phenotype. We recommend creating a ‘M.E.T.A’, i.e. metabolic, epigenetic, transcriptional and activation-based set of phenotypic markers for use in capturing the surface profiles, and cytokine production and killing activities of exhausted T cells generated in vitro. These four sets of markers comprise overlapping measures of exhaustion so that if at least two of these criteria are met, there will likely be good agreement that truly exhausted-state T cells are being studied. We note that as our manuscript was under review, an approach to generate exhausted mouse T cells through stimulation with live antigen-pulsed dendritic cells in vitro over 7 days was established by Wu et al. [162]. This preprint serves as an exemplar case for our M.E.T.A analysis as they examined three out of four markers (i.e. ETA) in their T cells at the endpoint of their stimulation regime. Given the physiological relevance of their in vitro approach, they then went on to identify mechanistic insights into regulators of T-cell exhaustion via a CRISPR screen [162].
Figure 2.
Summary of the different approaches to generate/isolate exhausted T cells. The methods can be broadly divided into ex vivo and in vitro approaches. In an ex vivo approach exhausted T cells are either isolated from well-established mouse models of exhaustion or from human patients whereas in an in vitro approach, exhausted cells are generated through different activation regiments as summarized.
Overall, with consistent and agreed protocols, it should be possible to perform experiments that are comparable across laboratories, particularly as the field moves towards more complicated systems incorporating more environmental factors in the study of T-cell exhaustion.
Contributor Information
Edward Jenkins, Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.
Toby Whitehead, Medical Research Council Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Martin Fellermeyer, Medical Research Council Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Simon J Davis, Medical Research Council Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Sumana Sharma, Medical Research Council Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Author contributions
Edward Jenkins (Conceptualization [equal], Writing—original draft [equal], Writing—review & editing [equal]), Toby Whitehead (Writing—original draft [supporting], Writing—review & editing [equal]), Martin Fellermeyer (Visualization [lead], Writing—original draft [supporting], Writing—review & editing [equal]), Simon J. Davis (Supervision [lead], Writing—review & editing [equal]), and Sumana Sharma (Conceptualization [equal], Supervision [supporting], Writing—original draft [equal], Writing—review & editing [equal])
Funding
E.J. and S.S. are funded by a Wellcome Trust Sir Henry Wellcome Fellowship (grant references 224040/Z/21/Z and 215883/Z/19/Z, respectively).
Conflict of interest statement
The authors declare no conflict of interest.
References
- 1. Moskophidis D, Lechner F, Pircher H et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758–61. [DOI] [PubMed] [Google Scholar]
- 2. Zajac AJ, Blattman JN, Murali-Krishna K et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Long AH, Haso WM, Shern JF et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015;21:581–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Lynn RC, Weber EW, Sotillo E et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 2019;576:293–300. Available from: 10.1038/s41586-019-1805-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Weber EW, Parker KR, Sotillo E et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science [Internet] 2021;372:eaba1786. Available from: 10.1126/science.aba1786 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Blank CU, Haining WN, Held W et al. Defining “T cell exhaustion.” Nat Rev Immunol 2019;19:665–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Im SJ, Hashimoto M, Gerner MY et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016;537:417–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Utzschneider DT, Charmoy M, Chennupati V et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 2016;45:415–27. [DOI] [PubMed] [Google Scholar]
- 9. McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 2019;37:457–95. [DOI] [PubMed] [Google Scholar]
- 10. Nagasaki J, Togashi Y. A variety of “exhausted” T cells in the tumor microenvironment. Int Immunol 2022;34:563–70. [DOI] [PubMed] [Google Scholar]
- 11. Seo W, Jerin C, Nishikawa H. Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. Exp Mol Med 2021;53:202–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Macián F, García-Rodríguez C, Rao A. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 2000;19:4783–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Oestreich KJ, Yoon H, Ahmed R et al. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Martinez GJ, Pereira RM, Äijö T et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 2015;42:265–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Man K, Gabriel SS, Liao Y et al. Transcription factor IRF4 promotes CD8+ T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity 2017;47:1129–41.e5. [DOI] [PubMed] [Google Scholar]
- 16. Quigley M, Pereyra F, Nilsson B et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010;16:1147–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Chen J, López-Moyado IF, Seo H et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 2019;567:530–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Kao C, Oestreich KJ, Paley MA et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011;12:663–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Paley MA, Kroy DC, Odorizzi PM et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012;338:1220–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Doering TA, Crawford A, Angelosanto JM et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012;37:1130–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. McLane LM, Ngiow SF, Chen Z et al. Role of nuclear localization in the regulation and function of T-bet and EOMES in exhausted CD8 T cells. Cell Rep 2021;35:109120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Chen Z, Ji Z, Ngiow SF et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 2019;51:840–55.e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Khan O, Giles JR, McDonald S et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 2019;571:211–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Seo H, Chen J, González-Avalos E et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA 2019;116:12410–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Scott AC, Dündar F, Zumbo P et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 2019;571:270–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Alfei F, Kanev K, Hofmann M et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 2019;571:265–9. [DOI] [PubMed] [Google Scholar]
- 27. Yao C, Sun HW, Lacey NE et al. Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection. Nat Immunol 2019;20:890–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Beltra JC, Manne S, Hakeem MSA et al. Developmental relationships of four exhausted CD8 T cell subsets reveals underlying transcriptional and epigenetic control mechanisms. J Immunol 2020;204(1_Supplement):77.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Grusdat M, McIlwain DR, Xu HC et al. IRF4 and BATF are critical for CD8+ T-cell function following infection with LCMV. Cell Death Differ 2014;21:1050–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Jadhav RR, Im SJ, Hu B et al. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci USA 2019;116:14113–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Chen Y, Zander RA, Wu X et al. BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. Nat Immunol 2021;22:996–1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Seo H, González-Avalos E, Zhang W et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 2021;22:983–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Miller BC, Sen DR, Al Abosy R et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 2019;20:326–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol 2009;21:179–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61. [DOI] [PubMed] [Google Scholar]
- 36. Blackburn SD, Shin H, Haining WN et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Greten TF. Immunotherapy of Hepatocellular Carcinoma. Springer, 2017, 167 p. [Google Scholar]
- 38. Roe K. NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion—the differences and similarities. Immunology 2022;166:155–68. [DOI] [PubMed] [Google Scholar]
- 39. Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 2011;34:466–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015;212:1125–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 2003;170:477–86. [DOI] [PubMed] [Google Scholar]
- 42. Wherry EJ, Blattman JN, Murali-Krishna K et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Mackerness KJ, Cox MA, Lilly LM et al. Pronounced virus-dependent activation drives exhaustion but sustains IFN-γ transcript levels. J Immunol 2010;185:3643–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Wang Y, Hu J, Li Y et al. The transcription factor TCF1 preserves the effector function of exhausted CD8 T cells during chronic viral infection. Front Immunol 2019;10:169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Wherry EJ, Barber DL, Kaech SM et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004;101:16004–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Bengsch B, Johnson AL, Kurachi M et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 2016;45:358–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Patsoukis N, Brown J, Petkova V et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 2012;5:ra46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Patsoukis N, Bardhan K, Chatterjee P et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015;6:6692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Yu YR, Imrichova H, Wang H et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol 2020;21:1540–51. [DOI] [PubMed] [Google Scholar]
- 50. Chowdhury PS, Chamoto K, Kumar A et al. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy. Cancer Immunol Res 2018;6:1375–87. [DOI] [PubMed] [Google Scholar]
- 51. Scharping NE, Rivadeneira DB, Menk AV et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 2021;22:205–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Sen DR, Kaminski J, Barnitz RA et al. The epigenetic landscape of T cell exhaustion. Science 2016;354:1165–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Philip M, Fairchild L, Sun L et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017;545:452–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Pauken KE, Sammons MA, Odorizzi PM et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 2016;354:1160–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Ghoneim HE, Fan Y, Moustaki A et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 2017;170:142–57.e19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Dolina JS, Van Braeckel-Budimir N, Thomas GD et al. CD8+ T cell exhaustion in cancer. Front Immunol 2021;12:715234. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Ford BR, Vignali PDA, Rittenhouse NL et al. Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Sci Immunol 2022;7:eabj9123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Fuertes Marraco SA, Neubert NJ, Verdeil G et al. Inhibitory receptors beyond T cell exhaustion. Front Immunol 2015;6:310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Gallimore A, Glithero A, Godkin A et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682–7. [DOI] [PubMed] [Google Scholar]
- 61. Wherry EJ, Ha SJ, Kaech SM et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27:670–84. [DOI] [PubMed] [Google Scholar]
- 62. Agnellini P, Wolint P, Rehr M et al. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc Natl Acad Sci USA 2007;104:4565–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Utzschneider DT, Legat A, Fuertes Marraco SA et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 2013;14:603–10. [DOI] [PubMed] [Google Scholar]
- 64. Staron MM, Gray SM, Marshall HD et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 2014;41:802–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Schietinger A, Philip M, Krisnawan VE et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 2016;45:389–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Sandu I, Cerletti D, Oetiker N et al. Landscape of exhausted virus-specific CD8 T cells in chronic LCMV infection. Cell Rep 2020;32:108078. [DOI] [PubMed] [Google Scholar]
- 67. Gerlach JT, Diepolder HM, Jung M et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117:933–41. [DOI] [PubMed] [Google Scholar]
- 68. Goepfert PA, Bansal A, Edwards BH et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 2000;74:10249–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Shankar P, Russo M, Harnisch B et al. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood 2000;96:3094–101. [PubMed] [Google Scholar]
- 70. Lechner F, Gruener NH, Urbani S et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000;30:2479–87. [DOI] [PubMed] [Google Scholar]
- 71. Kostense S, Ogg GS, Manting EH et al. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 2001;31:677–86. [DOI] [PubMed] [Google Scholar]
- 72. Gruener NH, Lechner F, Jung MC et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Zhang D, Shankar P, Xu Z et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 2003;101:226–35. [DOI] [PubMed] [Google Scholar]
- 74. Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006;44:126–39. [DOI] [PubMed] [Google Scholar]
- 75. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350–4. [DOI] [PubMed] [Google Scholar]
- 76. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Ye B, Liu X, Li X et al. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 2015;6:e1694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677–85. [DOI] [PubMed] [Google Scholar]
- 79. Zippelius A, Batard P, Rubio-Godoy V et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865–73. [DOI] [PubMed] [Google Scholar]
- 80. Yamamoto R, Nishikori M, Kitawaki T et al. PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111:3220–4. [DOI] [PubMed] [Google Scholar]
- 81. Appay V, Jandus C, Voelter V et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006;177:1670–8. [DOI] [PubMed] [Google Scholar]
- 82. Gandhi MK, Lambley E, Duraiswamy J et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006;108:2280–9. [DOI] [PubMed] [Google Scholar]
- 83. Gehring AJ, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009;137:682–90. [DOI] [PubMed] [Google Scholar]
- 84. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Zhang Y, Huang S, Gong D et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 2010;107:7875–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Baitsch L, Baumgaertner P, Devêvre E et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest 2011;121:2350–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89. Riches JC, Davies JK, McClanahan F et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Giordano M, Henin C, Maurizio J et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J 2015;34:2042–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Huang AC, Postow MA, Orlowski RJ et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Satpathy AT, Granja JM, Yost KE et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat Biotechnol 2019;37:925–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Oliveira G, Stromhaug K, Klaeger S et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 2021;596:119–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Mumprecht S, Schürch C, Schwaller J et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009;114:1528–36. [DOI] [PubMed] [Google Scholar]
- 95. Mognol GP, Spreafico R, Wong V et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc Natl Acad Sci USA 2017;114:E2776–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96. Cheng D, Qiu K, Rao Y et al. Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma. Elife [Internet]. 2023;12:e82705. Available from: 10.7554/eLife.82705 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. Guo X, Zhang Y, Zheng L et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med 2018;24:978–85. [DOI] [PubMed] [Google Scholar]
- 98. Li H, van der Leun AM, Yofe I et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 2019;176:775–89.e18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Hung MH, Lee JS, Ma C et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun 2021;12:1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Tietscher S, Wagner J, Anzeneder T et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun 2023;14:98. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101. Zhao M, Kiernan CH, Stairiker CJ et al. Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation. PLoS Pathog 2020;16:e1008555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102. Belk JA, Yao W, Ly N et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 2022;40:768–86.e7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Trefny MP, Kirchhammer N, Auf der Maur P et al. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. Nat Commun 2023;14:86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104. Siska PJ, van der Windt GJW, Kishton RJ et al. Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J Immunol 2016;197:2532–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105. Ma X, Bi E, Lu Y et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab 2019;30:143–56.e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106. Kersten K, Hu KH, Combes AJ et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell 2022;40:624–38.e9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107. Bell HN, Huber AK, Singhal R et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab 2023;35:134–49.e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108. Balkhi MY, Wittmann G, Xiong F et al. YY1 upregulates checkpoint receptors and downregulates Type I cytokines in exhausted, chronically stimulated human T cells. iScience 2018;2:105–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109. Corselli M, Saksena S, Nakamoto M et al. Single cell multiomic analysis of T cell exhaustion in vitro. Cytometry A 2022;101:27–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110. Vardhana SA, Hwee MA, Berisa M et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol 2020;21:1022–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112. Zha Y, Marks R, Ho AW et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006;7:1166–73. [DOI] [PubMed] [Google Scholar]
- 113. Lim JF, Berger H, Su IH. Isolation and activation of murine lymphocytes. J Vis Exp 2016;116:e54596. Available from: 10.3791/54596 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114. Usherwood EJ, Hogg TL, Woodland DL. Enumeration of antigen-presenting cells in mice infected with Sendai virus. J Immunol 1999;162:3350–5. [PubMed] [Google Scholar]
- 115. Nah J, Seong RH. Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells. Sci Adv 2022;8:eadc9346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116. Chen JL, Stewart-Jones G, Bossi G et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005;201:1243–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117. Zheng L, Qin S, Si W et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021;374:abe6474. [DOI] [PubMed] [Google Scholar]
- 118. Yu YYL, Netuschil N, Lybarger L et al. Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol 2002;168:3145–9. [DOI] [PubMed] [Google Scholar]
- 119. Kotowski M, Sharma S. CRISPR-based editing techniques for genetic manipulation of primary T cells. Methods Protoc [Internet] 2020;3:79. Available from: 10.3390/mps3040079 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121. Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife [Internet] 2020;9:e55185. Available from: 10.7554/eLife.55185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122. Jiang W, He Y, He W et al. Exhausted CD8+T cells in the tumor immune microenvironment: New pathways to therapy. Front Immunol 2020;11:622509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010;129:474–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124. Ejrnaes M, Filippi CM, Martinic MM et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006;203:2461–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125. Sawant DV, Yano H, Chikina M et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 2019;20:724–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126. Ho PC, Bihuniak JD, Macintyre AN et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015;162:1217–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol 2016;16:599–611. [DOI] [PubMed] [Google Scholar]
- 128. Pucino V, Certo M, Bulusu V et al. Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4+ T cell metabolic rewiring. Cell Metab 2019;30:1055–74.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129. Franco F, Jaccard A, Romero P et al. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab 2020;2:1001–12. [DOI] [PubMed] [Google Scholar]
- 130. Lötscher J, Martí I Líndez AA, Kirchhammer N et al. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. Cell 2022;185:585–602.e29. [DOI] [PubMed] [Google Scholar]
- 131. Reinfeld BI, Madden MZ, Wolf MM et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 2021;593:282–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132. Zhang Z, Liu S, Zhang B et al. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol 2020;8:17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133. Dorhoi A, Du Plessis N. Monocytic myeloid-derived suppressor cells in chronic infections. Front Immunol 2017;8:1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33:119–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136. Broz ML, Binnewies M, Boldajipour B et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014;26:938. [DOI] [PubMed] [Google Scholar]
- 137. Benner B, Scarberry L, Suarez-Kelly LP et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer 2019;7:140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138. Zhu J, Inomata T, Fujimoto K et al. Ex vivo-induced bone marrow-derived myeloid suppressor cells prevent corneal allograft rejection in mice. Invest Ophthalmol Vis Sci 2021;62:3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139. Reuven O, Mikula I Jr, Ashkenazi-Preiser H et al. Functional assays evaluating immunosuppression mediated by myeloid-derived suppressor cells. Curr Protoc 2022;2:e557. [DOI] [PubMed] [Google Scholar]
- 140. Bronte V, Brandau S, Chen SH et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141. Harrison RG. Observations on the living developing nerve fiber. Proc Soc Exp Biol Med 1906;4:140–3. [Google Scholar]
- 142. Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci 2020;7:33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143. Rodrigues J, Heinrich MA, Teixeira LM et al. 3D in vitro model (r)evolution: unveiling tumor–stroma interactions. Trends Cancer Res 2021;7:249–64. [DOI] [PubMed] [Google Scholar]
- 144. Friedrich J, Seidel C, Ebner R et al. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009;4:309–24. [DOI] [PubMed] [Google Scholar]
- 145. Katt ME, Placone AL, Wong AD et al. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol 2016;4:12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146. Ou L, Wang H, Huang H et al. Preclinical platforms to study therapeutic efficacy of human γδ T cells. Clin Transl Med 2022;12:e814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147. Murphy RJ, Gunasingh G, Haass NK et al. Formation and growth characteristics of co-culture tumour spheroids [Internet]. bioRxiv 2022. Available from: https://www.biorxiv.org/content/10.1101/2022.12.21.521515.abstract
- 148. Dijkstra KK, Cattaneo CM, Weeber F et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 2018;174:1586–98.e12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149. LeSavage BL, Suhar RA, Broguiere N et al. Next-generation cancer organoids. Nat Mater 2022;21:143–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150. Neal JT, Li X, Zhu J et al. Organoid modeling of the tumor immune microenvironment. Cell 2018;175:1972–88.e16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151. Chakrabarti J, Holokai L, Syu L et al. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 2018;9:37439–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152. Tsai S, McOlash L, Palen K et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 2018;18:335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153. De Crignis E, Hossain T, Romal S et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife [Internet] 2021;10:e60747. Available from: 10.7554/eLife.60747 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154. Broutier L, Andersson-Rolf A, Hindley CJ et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 2016;11:1724–43. [DOI] [PubMed] [Google Scholar]
- 155. Huch M, Koo BK. Modeling mouse and human development using organoid cultures. Development 2015;142:3113–25. [DOI] [PubMed] [Google Scholar]
- 156. Natarajan V, Simoneau CR, Erickson AL et al. Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system. Open Biol 2022;12:210320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157. Mahalingam SS, Jayaraman S, Bhaskaran N et al. Polyamine metabolism impacts T cell dysfunction in the oral mucosa of people living with HIV. Nat Commun 2023;14:399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158. Fardoos R, Nyquist SK, Asowata OE et al. HIV specific CD8+ TRM-like cells in tonsils express exhaustive signatures in the absence of natural HIV control. Front Immunol 2022;13:912038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159. Ayuso JM, Rehman S, Virumbrales-Munoz M et al. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion. Sci Adv [Internet]. 2021;7:eabc2331. Available from: 10.1126/sciadv.abc2331 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160. Lee J, Kim SE, Moon D et al. A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues. Lab Chip 2021;21:2142–52. [DOI] [PubMed] [Google Scholar]
- 161. Pritykin Y, van der Veeken J, Pine AR et al. A unified atlas of CD8 T cell dysfunctional states in cancer and infection. Mol Cell 2021;81:2477–93.e10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 162. Wu JE, Manne S, Ngiow SF et al. In vitro modeling of CD8 T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40. bioRxiv [Internet]. 2023. Available from: 10.1101/2023.04.17.537229 [DOI] [PMC free article] [PubMed]


